A FAIR Multi-Assay Dataset and Reproducibility Audit of Mucosal and Systemic Immune Responses After Oral Hyperimmune Anti-HIV-1 gp120 IgY Administration in Outbred Cats

<jats:p>Open, provenance-aware datasets are essential for evaluating biological findings and identifying analytical decisions that alter interpretation. This Data Resource Article describes a curated multi-assay preclinical dataset derived from studies of oral hyperimmune anti-human immunodeficiency virus type 1 (HIV-1) gp120 immunoglobulin Y (IgY) administration in outbred domestic cats. The publicly deposited Figshare resource comprises 13 comma-separated-value tables, a structured Excel workbook, a machine-readable data dictionary, provenance and quality-control records, executable Python and R scripts, a manifest and cryptographic checksums. Two independent cohorts are represented. A six-cat proof-of-concept cohort (three immunised and three controls) generated serum anti-gp120 anti-anti-idiotypic antibody (Ab3) ELISA data, competitive-inhibition measurements and processed TZM-bl HIV-1 JR-FL pseudovirus neutralisation outputs, including RLU summaries, virus-only and cell-only controls, percentage neutralisation and an estimated ID50. A separate 42-cat mucosal-immunogenicity cohort (18 immunised and 24 controls) generated salivary anti-gp120 IgA classifications after eight weeks of assigned oral exposure. Exact source values were transcribed with explicit provenance, whereas unavailable primary measurements were represented by schema-defined blanks rather than imputed observations. Reanalysis reproduced complete separation in IgA positivity (18/18 versus 0/24; Fisher exact p = 2.83 × 10−12; absolute risk difference 100%) and identified decision-sensitive analytical features. Displayed Ab3 negative wells yielded a mean-plus-three-standard-deviations threshold of 0.146, compared with source thresholds of 0.32 and 0.35. Animal-level competitive-inhibition means produced p = 0.0118 by Welch’s t-test and p = 0.10 by an exact Mann-Whitney test. The resource supports immunological reuse, assay benchmarking and transparent sensitivity analysis while preserving clear boundaries between reported, processed, derived and unavailable primary measurements. It should be interpreted as an exploratory FAIR-oriented data resource rather than evidence of vaccine efficacy or broadly neutralising immunity.</jats:p>